{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=120",
    "query": {
      "intervention": "Control Capsules",
      "page": 120
    },
    "page_size": 10
  },
  "pagination": {
    "page": 120,
    "page_size": 10,
    "total_count": 2912,
    "total_pages": 292,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=121&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Capsules&page=119&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-10T14:19:22.056Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02025907",
      "title": "A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin, 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin, 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 218,
      "start_date": "2014-02",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 30,
      "location_summary": "Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02025907"
    },
    {
      "nct_id": "NCT04083339",
      "title": "Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Cardiomyopathies"
      ],
      "interventions": [
        {
          "name": "AT-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Applied Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 675,
      "start_date": "2019-09-20",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2022-12-08",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 28,
      "location_summary": "Beverly Hills, California • La Jolla, California • Lincoln, California + 20 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lincoln",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tarzana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04083339"
    },
    {
      "nct_id": "NCT04233957",
      "title": "Dietary Sodium, Oxidative Stress, and Pulsatile Hemodynamics",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sodium Excess"
      ],
      "interventions": [
        {
          "name": "High Sodium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "University of Delaware",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 50,
      "start_date": "2020-01-01",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-11-29",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 1,
      "location_summary": "Newark, Delaware",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04233957"
    },
    {
      "nct_id": "NCT05055128",
      "title": "A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Erosive Esophagitis"
      ],
      "interventions": [
        {
          "name": "X842",
          "type": "DRUG"
        },
        {
          "name": "X842 Dummy",
          "type": "DRUG"
        },
        {
          "name": "Lansoprazole",
          "type": "DRUG"
        },
        {
          "name": "Lansoprazole Dummy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cinclus Pharma Holding AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 248,
      "start_date": "2021-08-11",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05055128"
    },
    {
      "nct_id": "NCT00962637",
      "title": "Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Hypogonadism"
      ],
      "interventions": [
        {
          "name": "Androxal",
          "type": "DRUG"
        },
        {
          "name": "AndroGel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Repros Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "68 Years",
        "sex": "MALE",
        "summary": "18 Years to 68 Years · Male only"
      },
      "enrollment_count": 194,
      "start_date": "2006-03",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2010-02-11",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00962637"
    },
    {
      "nct_id": "NCT02008565",
      "title": "Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fecal Incontinence"
      ],
      "interventions": [
        {
          "name": "Loperamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Anal exercises with biofeedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "NICHD Pelvic Floor Disorders Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2014-02",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-11-20",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • La Jolla, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02008565"
    },
    {
      "nct_id": "NCT07471048",
      "title": "A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Oral supplement containing 200mg Magnolia officinalis bark extract",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Sirt3 LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2026-03-01",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 1,
      "location_summary": "Englewood, New Jersey",
      "locations": [
        {
          "city": "Englewood",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07471048"
    },
    {
      "nct_id": "NCT01128985",
      "title": "A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Canagliflozin 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2010-03",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-05-29",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 2,
      "location_summary": "Fort Myers, Florida • Miramar, Florida",
      "locations": [
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01128985"
    },
    {
      "nct_id": "NCT00690443",
      "title": "Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 44,
      "start_date": "2008-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 5,
      "location_summary": "Pinellas Park, Florida • Edina, Minnesota • Mogadore, Ohio + 2 more",
      "locations": [
        {
          "city": "Pinellas Park",
          "state": "Florida"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        },
        {
          "city": "Mogadore",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00690443"
    },
    {
      "nct_id": "NCT00473460",
      "title": "Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases",
        "Bronchitis, Chronic"
      ],
      "interventions": [
        {
          "name": "Avelox (Moxifloxacin, BAY12-8039)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "45 Years to 90 Years"
      },
      "enrollment_count": 1404,
      "start_date": "2004-10",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2014-10-28",
      "last_synced_at": "2026-11-10T14:19:22.056Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bay Pines",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00473460"
    }
  ]
}